NEW YORK (GenomeWeb) – Illumina said on Sunday that it has launched a new company called Grail, which will develop a next-generation sequencing blood-based screening test for early cancer detection.

Grail has raised more than $100 million in a Series A financing round from Arch Venture Partners and Illumina, which contributed $40 million. Bezos Expeditions, Bill Gates, and Sutter Hill Ventures also invested in Grail.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.

John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.

Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.

In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.